In this article, we will explore 10 penny stocks with potential to rise 1000 percent.

Penny stocks can produce eye-catching bursts of upside, but their record against the broader market is usually weaker once you zoom out. Using BlackRock ETF proxies for comparison, the iShares Micro-Cap ETF returned 22.8% in 2025, ahead of the iShares Core S&P 500 ETF’s 17.9%, but over 10 years, the micro-cap fund annualized 9.4% versus 14.8% for the S&P 500 proxy. Risk was also much higher: the micro-cap fund’s three-year standard deviation was 22.5%, versus 12.0% for the S&P 500 fund. The SEC also notes that penny stocks tend to be less liquid, more volatile, and easier to manipulate, while academic work on lottery-like stocks has generally found lower future returns despite their appeal to speculators.

A large share of penny-stock growth stories tends to cluster in biotech and AI for structural reasons. In BlackRock’s micro-cap proxy, health care was the largest sector at 30.4%, while information technology accounted for 15.1%. Biotech fits the penny-stock mold because many firms are pre-revenue, cash-burning, and valued mainly on clinical milestones rather than current earnings. AI attracts similar speculative flows from the other direction: investors are trying to price in a rapidly expanding market, with Gartner projecting global AI spending of $2.52 trillion in 2026, up 44% year over year. In both cases, small companies can move sharply because expectations shift faster than fundamentals.

Methodology

We used consensus sentiment from Wall Street analysts and financial media websites to compile our list of penny stocks with the potential to rise 1000 percent over the next few years. We then limited our final selection to companies that have recently reported noteworthy developments likely to affect investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the penny stocks with the potential to rise 1000 percent.

On March 27, Rocket Pharmaceuticals said the FDA approved KRESLADI for a rare pediatric disorder, giving the company its first marketed product and a key regulatory win after a long review path. The company said the approval also makes KRESLADI the first FDA-approved gene therapy for this condition, which gives Rocket a commercial foothold in an ultra-rare disease market.

The bigger takeaway is what came with the approval. Rocket said it also received a Rare Pediatric Disease Priority Review Voucher, an asset biotech companies can monetize, and management said it is evaluating strategic options for the voucher to enhance financial flexibility. The company added that it plans to make KRESLADI available to eligible U.S. patients.

Rocket has also been signaling a measured launch rather than a broad commercial push. Recent company disclosures described a scaled commercial effort tailored to the very small patient population, while Reuters reported the rollout is expected to begin through a limited number of specialized centers. As of December 31, 2025, Rocket had $188.9 million in cash, cash equivalents, and investments.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a biotechnology company focused on genetic therapies for rare disorders. Its pipeline includes lentiviral and AAV-based programs targeting immunologic and cardiovascular diseases.

9. Datavault AI Inc. (NASDAQ:DVLT)

Datavault AI Inc. (NASDAQ:DVLT) is one of the penny stocks with the potential to rise 1000 percent.

On March 19, 2026, Datavault AI reported its first profitable quarter and record revenue growth for fiscal 2025. The company said fourth-quarter revenue reached $33.8 million, up 3,650% year over year, while operating profit improved to $4.2 million from a $6.3 million loss a year earlier. It also reported a net profit of $661 thousand for the quarter, which it described as the first in its history. For the full-year 2025, revenue rose 1,362% to $39.1 million, while gross profit reached $30 million, with a gross margin of about 78%.

The company also pointed to a stronger balance sheet at year-end, with about $116 million in working capital, $142.9 million in current assets, $26.9 million in current liabilities, and no long-term debt. On outlook, Datavault AI reiterated its full-year 2026 revenue target of $200 million, which it said would represent nearly 400% year-over-year growth from fiscal 2025. That target is management guidance and, as the company noted, remains subject to forward-looking risks and uncertainties.

Datavault AI Inc. (NASDAQ:DVLT) develops AI-driven data monetization, credentialing, digital engagement, and tokenization technologies through its Acoustic Sciences and Data Sciences divisions. The company is headquartered in Philadelphia.